During this briefing, Chief Executive Officer, Doug Ward, Chief Financial Officer, Barrie Lambert, Senior VP Commercial Operations, Paul Kase, and VP Medical Affairs, Annie Bell provide an overview of the FY25 results and a general business update.
Company News
Lumos FY25 Results Investor Briefing
03 Sep 2025
Keep reading
More news & media.
A few more pieces along the same thread. See the full index for everything.
COMPANY NEWS
1 min read
MST Access research report
MST Access has published a research report on Lumos Diagnostics Limited.
LD
Lumos Diagnostics Communications
Written with AI assistance
COMPANY NEWS
2 min read
FebriDx® Commercial Traction Continues to Advance
Lumos Diagnostics has announced further progress in the U.S. commercialisation of FebriDx® across its priority top-100 urgent care target list.
LD
Lumos Diagnostics Communications
Written with AI assistance
COMPANY NEWS
1 min read
REPLAY | FebriDx US Launch Update
Lumos CEO Doug Ward, Lumos Chief Commercial Officer Paul Kase, Lumos Director of U.S. Sales
LD
Lumos Diagnostics Communications
Written with AI assistance